Quest Diagnostics completed its previously announced acquisition of key assets from Boston biotech PathAI Diagnostics.

Quest Diagnostics (DGX) is a strong buy with growth potential, solid margins, and dividend increases. Discover the full ...

Quest Diagnostics DGX recently announced the completion of its acquisition of LifeLabs from OMERS. The transaction was valued at approximately $1 billion, including net debt.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at ...

Quest Diagnostics Inc. DGX is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company’s growth strategy includes pursuing ...

--Quest Diagnostics, a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a ...

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people ...

Quest Diagnostics DGX has shown impressive momentum in the past year, with its shares rallying 27.3%. The performance outpaces the industry’s 5.9% rise and the S&P 500 composite’s 12.3% gain. Carrying ...

Quest Diagnostics is a leading provider of independent diagnostic testing in the United States thanks to its network of roughly 2,300 patient service centers across the country. We think its size ...

SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of ...

With the acquisition, Quest broadens access to its industry-leading and innovative test menu, network of convenient patient access sites and broad health plan coverage in Ohio.

In this press release, we (Quest Diagnostics or the Company) present financial information with respect to our projected adjusted EPS following the expected acquisition of LifeLabs.